Clover Health Investments, Corp. (CLOV) Stock Competitors & Peer Comparison
See (CLOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CLOV | $4.29 | +9.44% | 2.2B | -35.75 | -$0.12 | N/A |
| UNH | $413.00 | +1.58% | 375.1B | 31.08 | $13.29 | +2.17% |
| CVS | $97.06 | -0.02% | 123.8B | 42.57 | $2.28 | +2.71% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $424.43 | +1.50% | 92.2B | 18.00 | $23.58 | +1.70% |
| CI | $295.00 | +1.86% | 78B | 2.59 | $113.73 | +2.08% |
| HUM | $363.17 | +2.02% | 43.6B | 38.80 | $9.36 | +0.97% |
| CNC | $66.21 | +1.81% | 32.7B | -5.07 | -$13.05 | N/A |
| MOH | $203.06 | +2.34% | 10.6B | 54.44 | $3.73 | N/A |
| OSCR | $27.22 | -0.62% | 7.1B | -50.41 | -$0.54 | N/A |
Stock Comparison
CLOV vs UNH Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, UNH has a market cap of 375.1B. Regarding current trading prices, CLOV is priced at $4.29, while UNH trades at $413.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas UNH's P/E ratio is 31.08. In terms of profitability, CLOV's ROE is -0.17%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check UNH's competition here
CLOV vs CVS Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, CVS has a market cap of 123.8B. Regarding current trading prices, CLOV is priced at $4.29, while CVS trades at $97.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas CVS's P/E ratio is 42.57. In terms of profitability, CLOV's ROE is -0.17%, compared to CVS's ROE of +0.04%. Regarding short-term risk, CLOV is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CVS's competition here
CLOV vs ANTM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CLOV is priced at $4.29, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CLOV's ROE is -0.17%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to ANTM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check ANTM's competition here
CLOV vs ELV Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, ELV has a market cap of 92.2B. Regarding current trading prices, CLOV is priced at $4.29, while ELV trades at $424.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas ELV's P/E ratio is 18.00. In terms of profitability, CLOV's ROE is -0.17%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CLOV is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check ELV's competition here
CLOV vs CI Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, CI has a market cap of 78B. Regarding current trading prices, CLOV is priced at $4.29, while CI trades at $295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas CI's P/E ratio is 2.59. In terms of profitability, CLOV's ROE is -0.17%, compared to CI's ROE of +0.15%. Regarding short-term risk, CLOV is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CI's competition here
CLOV vs HUM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, HUM has a market cap of 43.6B. Regarding current trading prices, CLOV is priced at $4.29, while HUM trades at $363.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas HUM's P/E ratio is 38.80. In terms of profitability, CLOV's ROE is -0.17%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CLOV is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check HUM's competition here
CLOV vs CNC Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, CNC has a market cap of 32.7B. Regarding current trading prices, CLOV is priced at $4.29, while CNC trades at $66.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas CNC's P/E ratio is -5.07. In terms of profitability, CLOV's ROE is -0.17%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CLOV is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CNC's competition here
CLOV vs MOH Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, MOH has a market cap of 10.6B. Regarding current trading prices, CLOV is priced at $4.29, while MOH trades at $203.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas MOH's P/E ratio is 54.44. In terms of profitability, CLOV's ROE is -0.17%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CLOV is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check MOH's competition here
CLOV vs OSCR Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, OSCR has a market cap of 7.1B. Regarding current trading prices, CLOV is priced at $4.29, while OSCR trades at $27.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas OSCR's P/E ratio is -50.41. In terms of profitability, CLOV's ROE is -0.17%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CLOV is more volatile compared to OSCR. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check OSCR's competition here
CLOV vs ALHC Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, ALHC has a market cap of 4B. Regarding current trading prices, CLOV is priced at $4.29, while ALHC trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas ALHC's P/E ratio is 192.00. In terms of profitability, CLOV's ROE is -0.17%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CLOV is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CLOV.Check ALHC's competition here
CLOV vs BHG Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CLOV is priced at $4.29, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas BHG's P/E ratio is -0.12. In terms of profitability, CLOV's ROE is -0.17%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CLOV is more volatile compared to BHG. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check BHG's competition here
CLOV vs CABR Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, CABR has a market cap of 17.7M. Regarding current trading prices, CLOV is priced at $4.29, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas CABR's P/E ratio is -1.74. In terms of profitability, CLOV's ROE is -0.17%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CLOV is more volatile compared to CABR. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check CABR's competition here
CLOV vs BMGL Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, CLOV is priced at $4.29, while BMGL trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas BMGL's P/E ratio is -1.45. In terms of profitability, CLOV's ROE is -0.17%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CLOV is more volatile compared to BMGL. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check BMGL's competition here
CLOV vs MGLN Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CLOV is priced at $4.29, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CLOV's ROE is -0.17%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CLOV is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check MGLN's competition here
CLOV vs AET Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, AET has a market cap of 0. Regarding current trading prices, CLOV is priced at $4.29, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas AET's P/E ratio is N/A. In terms of profitability, CLOV's ROE is -0.17%, compared to AET's ROE of +0.11%. Regarding short-term risk, CLOV is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check AET's competition here
CLOV vs GTS Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CLOV is priced at $4.29, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas GTS's P/E ratio is 10.41. In terms of profitability, CLOV's ROE is -0.17%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CLOV is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check GTS's competition here
CLOV vs UAM Comparison June 2026
CLOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLOV stands at 2.2B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CLOV is priced at $4.29, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLOV currently has a P/E ratio of -35.75, whereas UAM's P/E ratio is N/A. In terms of profitability, CLOV's ROE is -0.17%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CLOV is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CLOV.Check UAM's competition here